glp-1 masld Two Pediatric Publications: Call for Action and Use of RAs The Interplay Between GLP-1-Based Therapies,

Lifevantage Mindbody GLP-1 System claims to have research behind it, and to an untrained eye, that research appears compelling

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

Ozempic is a medication that contains a synthetic form of this hormone called a GLP-1 receptor agonist

What They Are and Why Lifestyle Change is Key to Sustained Weight Loss